• AWS for biological samples, providing automated lab infrastructure.
• A specialized Thermo Fisher Scientific for automated sample management and genomic services.

• Automated Sample Storage Systems: Robotic systems designed for automated, secure, and precise storage and retrieval of biological samples at various temperatures.
• Sample Management Consumables: Specialized tubes, plates, seals, and labware optimized for high-integrity, automated handling and storage of biological samples.
• Genomic Sequencing Services: Comprehensive DNA and RNA sequencing services supporting various research, drug discovery, and clinical genomics applications.
• Gene Synthesis Services: Custom synthesis of genes and DNA fragments to facilitate research, therapeutic development, and industrial biotechnology projects.
• Oligonucleotide Synthesis: Production of custom synthetic DNA and RNA oligonucleotides for molecular biology research, diagnostics, and therapeutic development.
• Sample Biorepository Services: Outsourced services providing secure, compliant, and cold chain-managed collection, processing, and long-term storage of biological materials.

Azenta (symbol: AZTA) primarily sells its products and services to other companies and institutions (B2B).

Based on its latest SEC filings, Azenta does not disclose any single major customer company that accounts for 10% or more of its revenue. Instead, its customer base is diversified across a wide range of organizations within the life sciences sector. The major categories of customers that Azenta serves include:

• Global Pharmaceutical Companies: Large multinational corporations involved in the research, development, manufacturing, and marketing of pharmaceutical drugs. They utilize Azenta's sample management systems and genomic services for drug discovery and development.
• Biotechnology Companies: Firms focused on developing technology and products using biological systems, living organisms, or derivatives. These companies leverage Azenta's solutions for advanced biological research and product development.
• Academic Institutions: Universities, medical schools, and various other educational and research institutions that conduct scientific and biomedical research. They are key users of Azenta's sample storage and genomic sequencing services for their research projects.
• Contract Research Organizations (CROs): Companies that provide support to the pharmaceutical, biotechnology, and medical device industries in the form of outsourced research services. CROs often use Azenta's offerings to manage samples and perform genomic analysis for their clients.

null

John P. Marotta President & Chief Executive Officer

Mr. Marotta joined Azenta Life Sciences in September 2024 as President and CEO. He has two decades of experience leading global companies in life sciences, medical devices, and diagnostics. Prior to Azenta, Mr. Marotta served as Executive in Residence of Patient Square Capital, a healthcare investment firm. Previously, he was CEO and President of PHC Holdings Corporation (formerly Panasonic Health Care), a diversified global life sciences, diagnostics, and medical device company, where he oversaw its IPO from owners KKR Capital.

Lawrence Lin Executive Vice President & Chief Financial Officer

Mr. Lin joined Azenta in November 2024 as Executive Vice President and Chief Financial Officer, bringing over twenty years of finance experience. Before joining Azenta, he was Chief Financial Officer at GeoStabilization International LLC, a privately held industrial company, and Senior Vice President of Finance Operations at PHC Holdings Corporation. His prior roles also include Vice President of Finance for North America (CFO) and Global Functions at LivaNova, and Vice President of Finance Operations at KaVo Kerr, which was part of Danaher before being spun off as the independent public company Envista in 2019.

Dr. Ginger Zhou Senior Vice President, President GENEWIZ

Dr. Zhou joined Azenta Life Sciences in November 2018 as part of the acquisition of GENEWIZ and was appointed Senior Vice President and General Manager of the GENEWIZ Multiomics and Synthesis Solutions business in November 2022. She is responsible for leading global GENEWIZ business growth, operations, and development. During her seven years with GENEWIZ prior to the acquisition, Dr. Zhou held various leadership positions, including VP of Global Next Generation Sequencing.

Olga Pirogova Senior Vice President & Chief Human Resources Officer

Mrs. Pirogova joined Azenta Life Sciences in August 2023 as Senior Vice President and Chief Human Resources Officer (CHRO). She is responsible for developing and executing Azenta's human resources strategy. Prior to Azenta, Ms. Pirogova served as CHRO at Speedcast, a global satellite communications service provider.

1. Material Weakness in Internal Control Over Financial Reporting: Azenta has identified a material weakness in its internal control over financial reporting, specifically concerning the review of its cash flow statement. This issue raises significant concerns about the reliability of the company's financial reporting, potentially leading to increased scrutiny from regulators and stakeholders, and impacting investor confidence. The delay in filing its 10-K report further highlights this concern.
2. Macroeconomic Uncertainties and Fluctuations in Customer Spending: Azenta's business is vulnerable to broader macroeconomic uncertainties, including economic downturns and fluctuations in government funding for scientific research, such as NIH funding. These external factors can adversely affect customer spending and demand for Azenta's solutions, directly impacting its revenue and overall financial performance.
3. Intense Competition and Pricing Pressures: The life sciences solutions market, in which Azenta operates, is highly competitive. The company faces ongoing threats from existing and emerging competitors who may offer similar or more advanced solutions. This competitive landscape, combined with pricing headwinds in segments like Multiomics, can put pressure on Azenta's market share and profit margins.

The increasing trend for large academic institutions and pharmaceutical companies to establish and expand their own in-house genomic sequencing and analysis capabilities poses an emerging threat to Azenta's Genomic Services segment (GENEWIZ). As sequencing technologies become more accessible, cost-effective, and user-friendly, more customers are bringing high-volume and routine sequencing projects in-house rather than outsourcing them. This shift directly reduces the total addressable market for external genomic service providers like Azenta, potentially leading to pricing pressures and a contraction in demand for outsourced services over time.

Azenta (symbol: AZTA) operates in several addressable markets within the life sciences sector. The company's main products and services include genomics, cryogenic storage, automation, informatics, cold-chain sample management solutions, multiomics services, sample repository services (SRS), consumables and instruments, automated ultra-cold storage, and B Medical Systems (medical refrigeration and vaccine cold chain technology), and cell and gene therapy solutions.

• Total Addressable Market (Overall Azenta Portfolio): Azenta estimates its total addressable market to be approximately $10 billion globally by 2025, growing from an estimated $6 billion in 2021. This market includes Ultracold Stores, Consumables & Instruments, Genomics, and Sample Repository Services.

• Cell and Gene Therapy Market: The global cell and gene therapy market is projected to grow from $8.94 billion in 2025 to approximately $39.61 billion by 2034, at a compound annual growth rate (CAGR) of 17.98%. Another estimate places the global market at $19.47 billion in 2025, growing to $71.38 billion by 2032 at a CAGR of 19.95%. The U.S. cell and gene therapy market alone was estimated at $3.59 billion in 2024 and is predicted to reach around $16.93 billion by 2034, with a CAGR of 17.10%.

• Gene Therapy Market: Specifically, the global gene therapy market size is estimated at $9.74 billion in 2025 and is expected to reach $24.34 billion by 2030, with a CAGR of 20.11% during that forecast period.

• Cold-Chain Sample Management Solutions: Null (This market size is not separately identified but is a significant component within Azenta's overall $10 billion total addressable market, which includes Ultracold Stores and Sample Repository Services.)

• Multiomics Services (including Genomics): Null (Genomics is explicitly stated as a component of Azenta's overall $10 billion total addressable market.)

• Sample Repository Services (SRS): Null (This market size is explicitly stated as a component of Azenta's overall $10 billion total addressable market.)

• Consumables & Instruments: Null (This market size is explicitly stated as a component of Azenta's overall $10 billion total addressable market.)

• Automated Ultra-Cold Storage: Null (This market size is explicitly stated as a component of Azenta's overall $10 billion total addressable market.)

• B Medical Systems (Medical Refrigeration and Vaccine Cold Chain Technology): Null (B Medical Systems' portfolio includes medical refrigeration, blood management solutions, and vaccine transport systems, with over 500,000 units deployed in approximately 150 countries worldwide.)

• Sample Management LIMS (Limfinity, Freezer Pro): Null

Azenta (AZTA) is expected to drive future revenue growth over the next 2-3 years through several key strategic initiatives and market expansions:

1. Continued Growth in Sample Management Solutions: Azenta anticipates sustained revenue growth from its Sample Management Solutions segment. This includes significant contributions from automated storage systems, cryogenic stores, sample repository services, and sales of consumables and instruments. For example, cryogenic stores showed almost 40% growth in Q3 2024, reflecting increasing demand for automation in life sciences. The company has noted consistent double-digit year-over-year growth in store systems.
2. Expansion in Multiomics Services, particularly Next Generation Sequencing (NGS): The Multiomics segment, especially Next Generation Sequencing, is a significant driver of future revenue. Azenta has reported strong performance in NGS, with double-digit volume growth and price stabilization in recent quarters. This area is expected to continue its upward trajectory, contributing to the overall organic revenue growth.
3. Strategic Portfolio Optimization and Operational Excellence: While not a direct revenue driver, Azenta's focus on portfolio optimization, including the divestiture of its B Medical Systems business (now classified as discontinued operations), allows the company to concentrate resources on its higher-growth Sample Management Solutions and Multiomics segments. Initiatives such as the "Ascend 2026 transformation program" and ongoing operational efficiencies are aimed at improving profitability and providing a stronger foundation for accelerated growth in its core businesses.
4. Product Innovation and Strategic Investments: Azenta is actively investing in new products and expanding its capabilities within its core Sample Management and Multiomics businesses. The company has a "robust product funnel" and is making capital expenditures to invest for growth and scale in these segments, indicating an expectation of new offerings contributing to future revenue.

Share Repurchases

• In November 2022, Azenta authorized a $1.5 billion share repurchase program.
• The company initiated a $500 million accelerated share repurchase (ASR) program in November 2022.
• By September 2024, Azenta completed its $1.5 billion share repurchase program, having bought back 30.0 million shares.

Share Issuance

• No significant dollar amount of share issuances was explicitly detailed in the provided search results for the last 3-5 years, as the company's focus was on share repurchases.

Inbound Investments

• No specific large inbound investments by third-parties, such as strategic partners or private equity firms, were detailed in the provided information for the last 3-5 years.

Outbound Investments

• Azenta acquired B Medical Systems S.a.r.l. in October 2022 for approximately $422 million in cash.
• In October 2022, the company acquired Barkey for $84.2 million (net of cash acquired), entering the controlled-rate thawing business.
• The company is actively pursuing "tuck-in acquisitions" and "selective M&A opportunities" to broaden its product offerings and market reach.

Capital Expenditures

• Capital expenditures were $37 million in fiscal year 2024, $39 million in fiscal year 2023, and $73 million in fiscal year 2022.
• For the second quarter of fiscal 2025, capital expenditures were $7 million, and for the third quarter of fiscal 2025, they were $11 million.
• Primary focus areas for capital allocation include product innovations, advancements in sample management and genomics services, operational efficiencies, and digital enhancements.